ERBB2 and nasopharyngeal carcinoma: Recently, some studies have reported that, and targeting ERBB2 has the potential to sensitize NPC cells to chemotherapy and radiotherapy (Liu et al., 2016; Huang et al., 2019; Fu et al., 2021).